PPAR-γ, as a master regulator of hepatic lipid homeostasis, demonstrates therapeutic potential for NAFLD treatment through its anti-inflammatory, insulin-sensitizing, oxidative stress-alleviating, and fibrotic regression properties [66]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.